Kadcyla In pAtients With bRAin Metastasis
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Metastatic HER2-positive Breast Cancer With Brain Metastasis
Interventions: DRUG: KADCYLA 160 MG Injection
Sponsor: Jules Bordet Institute